<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>FEXMID - cyclobenzaprine hydrochloride tablet, film coated </strong><br>STAT Rx USA LLC<br></p></div>
<h1>Fexmid<span class="Sup">® </span>cyclobenzaprine HCl<br>7.5 mg Tablets USP
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s1"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Issued: October 2007</span></p>
<p><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION
</h1>
<p class="First">Fexmid<span class="Sup">®</span> (cyclobenzaprine hydrochloride) is a white, crystalline tricyclic amine salt. It has a melting point of 217°C, and a pK<span class="Sub">a</span> of 8.47 at 25°C. It is freely soluble in water and alcohol, sparingly soluble in isopropanol, and insoluble in hydrocarbon solvents. If aqueous solutions are made alkaline, the free base separates. Cyclobenzaprine HCl is designated chemically as 3-(5<span class="Italics">H</span>-dibenzo[<span class="Italics">a</span>,<span class="Italics">d</span>]cyclohepten-5-ylidene)-<span class="Italics">N</span>,<span class="Italics">N</span>-dimethyl-1-propanamine hydrochloride, and has the following structural formula:
</p>
<div class="Figure"><img alt="FEXMID Structure Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=615f1e2f-63ec-4e20-bb74-293b5baf1d43&amp;name=FEXMID%207.5%20MG%20STRUCTURE.jpg"></div>
<br><br><p>Fexmid is available for oral administration as 7.5 mg tablets. Fexmid contains the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, dibasic calcium phosphate, hydroxypropyl cellulose, hypromellose, polyethylene glycol, magnesium stearate, microcrystalline cellulose, and titanium dioxide.
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s3"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY
</h1>
<p class="First">Fexmid relieves skeletal <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasm</span> of local origin without interfering with muscle function. It is ineffective in <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasm</span> due to central nervous system disease.
</p>
<p>Cyclobenzaprine reduced or abolished skeletal muscle <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span> in several animal models. Animal studies indicate that cyclobenzaprine does not act at the neuromuscular junction or directly on skeletal muscle. Such studies show that cyclobenzaprine acts primarily within the central nervous system at brain stem as opposed to spinal cord levels, although its action on the latter may contribute to its overall skeletal muscle relaxant activity. Evidence suggests that the net effect of cyclobenzaprine is a reduction of tonic somatic motor activity, influencing both gamma (γ) and alpha (α) motor systems.
</p>
<p>Pharmacological studies in animals showed a similarity between the effects of cyclobenzaprine and the structurally related tricyclic antidepressants, including reserpine antagonism, norepinephrine potentiation, potent peripheral and central anticholinergic effects, and sedation. Cyclobenzaprine caused slight to moderate increase in heart rate in animals.
</p>
<div class="Section" data-sectionCode="43682-4">
<a name="s4"></a><a name="section-3.1"></a><p></p>
<h2>Pharmacokinetics
</h2>
<p class="First">Estimates of mean oral bioavailability of cyclobenzaprine range from 33% to 55%. Cyclobenzaprine exhibits linear pharmacokinetics over the dose range 2.5 mg to 10 mg, and is subject to enterohepatic circulation. It is highly bound to plasma proteins. Drug accumulates when dosed three times a day, reaching steady-state within 3-4 days at plasma concentrations about four-fold higher than after a single dose. At steady state in healthy subjects receiving 10 mg t.i.d. (n=18), peak plasma concentration was 25.9 ng/mL (range, 12.8-46.1 ng/mL), and area under the concentration-time (AUC) curve over an 8-hour dosing interval was 177 ng.hr/mL (range, 80-319 ng.hr/mL).
</p>
<p>Cyclobenzaprine is extensively metabolized, and is excreted primarily as glucuronides via the kidney. Cytochromes P-450 3A4, 1A2, and, to a lesser extent, 2D6, mediate N-demethylation, one of the oxidative pathways for cyclobenzaprine. Cyclobenzaprine is eliminated quite slowly, with an effective half-life of 18 hours (range 8-37 hours; n=18); plasma clearance is 0.7 L/min.
</p>
<p>The plasma concentration of cyclobenzaprine is generally higher in the elderly and in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. (See <span class="Bold"><a href="#s12">PRECAUTIONS, Use in the Elderly</a></span> and <span class="Bold"><a href="#s12">PRECAUTIONS, Impaired Hepatic Function</a></span>.)
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5"></a><a name="section-3.2"></a><p></p>
<h2>Elderly
</h2>
<p class="First">In a pharmacokinetic study in elderly individuals (≥65yrs old), mean (n=10) steady-state cyclobenzaprine AUC values were approximately 1.7 fold (171.0 ng.hr/mL, range 96.1 to 255.3) higher than those seen in a group of eighteen younger adults (101.4 ng.hr/mL, range 36.1 to 182.9) from another study. Elderly male subjects had the highest observed mean increase, approximately 2.4 fold (198.3 ng.hr/mL range 155.6 to 255.3 versus 83.2 ng.hr/mL, range 41.1 to 142.5 for younger males) while levels in elderly females were increased to a much lesser extent, approximately 1.2 fold (143.8 ng.hr/mL, range 96.1 to 196.3 versus 115.9 ng.hr/mL, range 36.1 to 182.9 for younger females).
</p>
<p>In light of these findings, therapy with cyclobenzaprine HCI in the elderly should be initiated with a 5 mg dose and titrated slowly upward.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6"></a><a name="section-3.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>
</h2>
<p class="First">In a pharmacokinetic study of sixteen subjects with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (15 mild, 1 moderate per Child-Pugh score), both AUC and C<span class="Sub">max</span> were approximately double the values seen in the healthy control group. Based on the findings, cyclobenzaprine HCI should be used with caution in subjects with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> starting with the 5 mg dose and titrating slowly upward. Due to the lack of data in subjects with more severe <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>, the use of Fexmid in subjects with moderate to severe impairment is not recommended.
</p>
<p>No significant effect on plasma levels or bioavailability of cyclobenzaprine HCl or aspirin was noted when single or multiple doses of the two drugs were administered concomitantly. Concomitant administration of cyclobenzaprine HCl and naproxen or diflunisal was well tolerated with no reported unexpected adverse effects. However combination therapy of cyclobenzaprine HCl with naproxen was associated with more side effects than therapy with naproxen alone, primarily in the form of <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>. No well-controlled studies have been performed to indicate that cyclobenzaprine HCl enhances the clinical effect of aspirin or other analgesics, or whether analgesics enhance the clinical effect of cyclobenzaprine HCl in acute musculoskeletal conditions.
</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s7"></a><a name="section-3.4"></a><p></p>
<h2>Clinical Studies
</h2>
<p class="First">Eight double-blind controlled clinical studies were performed in 642 patients comparing cyclobenzaprine HCl 10 mg, diazepam**, and placebo. <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle spasm</span>, local <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, limitation of motion: and restriction in activities of daily living were evaluated. In three of these studies there was a significantly greater improvement with cyclobenzaprine HCl than with diazepam, while in the other studies the improvement following both treatments was comparable.
</p>
<p>Although the frequency and severity of adverse reactions observed in patients treated with cyclobenzaprine HCl were comparable to those observed in patients treated with diazepam, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> was observed more frequently in patients treated with cyclobenzaprine HCl and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> more frequently in those treated with diazepam. The incidence of <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, the most frequent adverse reaction, was similar with both drugs.
</p>
<p>The efficacy of cyclobenzaprine HCl 5 mg was demonstrated in two seven-day, double-blind, controlled clinical trials enrolling 1405 patients. One study compared cyclobenzaprine HCl 5 and 10 mg t.i.d. to placebo; and a second study compared cyclobenzaprine HCl 5 and 2.5 mg t.i.d. to placebo. Primary end-points for both trials were determined by patient-generated data and included global impression of change, medication helpfulness, and relief from starting <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">backache</span>. Each endpoint consisted of a score on a 5-point rating scale (from 0 or worst outcome to 4 or best outcome). Secondary endpoints included a physician's evaluation of the presence and extent of palpable <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasm</span>.
</p>
<p>Comparisons of cyclobenzaprine HCl 5 mg and placebo groups in both trials established the statistically significant superiority of the 5 mg dose for all three primary endpoints at day 8 and, in the study comparing 5 and 10 mg, at day 3 or 4 as well. A similar effect was observed with cyclobenzaprine HCl 10 mg (all endpoints). Physician-assessed secondary endpoints also showed that cyclobenzaprine HCl 5 mg was associated with a greater reduction in palpable <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasm</span> than placebo.
</p>
<p>Analysis of the data from controlled studies shows that cyclobenzaprine HCl produces clinical improvement whether or not sedation occurs.
</p>
<p>**VALIUM<span class="Sup">®</span> (diazepam, Roche)
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s8"></a><a name="section-3.5"></a><p></p>
<h2>Surveillance Program
</h2>
<p class="First">A post-marketing surveillance program was carried out in 7607 patients with acute <span class="product-label-link" type="condition" conceptid="4244662" conceptname="Disorder of musculoskeletal system">musculoskeletal disorders</span>, and included 297 patients treated with cyclobenzaprine HCl 10 mg for 30 days or longer. The overall effectiveness of cyclobenzaprine HCI was similar to that observed in the double-blind controlled studies; the overall incidence of adverse effects was less (see <span class="Bold"><a href="#s23">ADVERSE REACTIONS</a></span>).
</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s9"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE
</h1>
<p class="First">Fexmid is indicated as an adjunct to rest and physical therapy for relief of <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasm</span> associated with acute, painful musculoskeletal conditions.
</p>
<p>Improvement is manifested by relief of <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasm</span> and its associated signs and symptoms: namely, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, limitation of motion, and restriction in activities of daily living.
</p>
<p><span class="Italics">Fexmid should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasm</span> associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted.</span></p>
<p>Fexmid has not been found effective in the treatment of <span class="product-label-link" type="condition" conceptid="4287788" conceptname="Spasticity">spasticity</span> associated with cerebral or spinal cord disease, or in children with <span class="product-label-link" type="condition" conceptid="4134120" conceptname="Cerebral palsy">cerebral palsy</span>.
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s10"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS
</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any component of this product.
</p>
<p>Concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after their discontinuation. Hyperpyretic crisis <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> have occurred in patients receiving cyclobenzaprine (or structurally similar tricyclic antidepressants) concomitantly with MAO inhibitor drugs.
</p>
<p>Acute recovery phase of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and patients with <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span> or conduction disturbances, or <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>.
</p>
<p><span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">Hyperthyroidism</span>.
</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s11"></a><a name="section-6"></a><p></p>
<h1>WARNINGS
</h1>
<p class="First">Fexmid is closely related to the tricyclic antidepressants, e.g., amitriptyline and imipramine. In short term studies for indications other than <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasm</span> associated with acute musculoskeletal conditions, and usually at doses somewhat greater than those recommended for skeletal <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasm</span>, some of the more serious central nervous system reactions noted with the tricyclic antidepressants have occurred (see <span class="Bold"><a href="#s11">WARNINGS,</a></span> below, and <span class="Bold"><a href="#s23">ADVERSE REACTIONS</a></span>).
</p>
<p>Tricyclic antidepressants have been reported to produce <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="4007310" conceptname="Sinus tachycardia">sinus tachycardia</span>, prolongation of the conduction time leading to <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>.
</p>
<p>Fexmid may enhance the effects of alcohol, barbiturates, and other CNS depressants.
</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s12"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="s13"></a><a name="section-7.1"></a><p></p>
<h2>General
</h2>
<p class="First">Because of its atropine-like action, Fexmid should be used with caution in patients with a history of <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, <span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">increased intraocular pressure</span>, and in patients taking anticholinergic medication.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s14"></a><a name="section-7.2"></a><p></p>
<h2>Impaired Hepatic Function
</h2>
<p class="First">The plasma concentration of cyclobenzaprine is increased in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (see <span class="Bold"><a href="#s4">CLINICAL PHARMACOLOGY, Pharmacokinetics,</a><a href="#s6"> <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></span>).
</p>
<p>These patients are generally more susceptible to drugs with potentially sedating effects, including cyclobenzaprine. Cyclobenzaprine HCl should be used with caution in subjects with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> starting with a 5 mg dose and titrating slowly upward. Due to the lack of data in subjects with more severe <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>, the use of Fexmid in subjects with moderate to severe impairment is not recommended.
</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s15"></a><a name="section-7.3"></a><p></p>
<h2>Information for Patients
</h2>
<p class="First">Fexmid, especially when used with alcohol or other CNS depressants, may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle. In the elderly, the frequency and severity of adverse events associated with the use of cyclobenzaprine, with or without concomitant medications, is increased. In elderly patients, cyclobenzaprine HCl should be initiated with a 5 mg dose and titrated slowly upward.
</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s16"></a><a name="section-7.4"></a><p></p>
<h2>Drug Interactions
</h2>
<p class="First">Fexmid may have life-threatening interactions with MAO inhibitors. (See <span class="Bold"><a href="#s10">CONTRAINDICATIONS.</a></span>)
</p>
<p>Fexmid may enhance the effects of alcohol, barbiturates, and other CNS depressants.
</p>
<p>Tricyclic antidepressants may block the antihypertensive action of guanethidine and similarly acting compounds.
</p>
<p>Tricyclic antidepressants may enhance the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> risk in patients taking tramadol.<span class="Sup">†</span></p>
<p><span class="Sup">†</span>ULTRAM<span class="Sup">®</span> (tramadol HCl tablets, Ortho-McNeil Pharmaceutical)
</p>
<p><span class="Sup">†</span>ULTRACET<span class="Sup">®</span> (tramadol HCl and acetaminophen tablets, Ortho-McNeil Pharmaceutical)
</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s17"></a><a name="section-7.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<p class="First">In rats treated with cyclobenzaprine HCl for up to 67 weeks at doses of approximately 5 to 40 times the maximum recommended human dose, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span>, sometimes enlarged, livers were noted and there was a dose-related hepatocyte vacuolation with <span class="product-label-link" type="condition" conceptid="4027782" conceptname="Lipid storage disease">lipidosis</span>. In the higher dose groups this microscopic change was seen after 26 weeks and even earlier in rats which died prior to 26 weeks; at lower doses, the change was not seen until after 26 weeks.
</p>
<p>Cyclobenzaprine did not affect the onset, incidence or distribution of neoplasia in an 81-week study in the mouse or in a 105-week study in the rat.
</p>
<p>At oral doses of up to 10 times the human dose, cyclobenzaprine did not adversely affect the reproductive performance or fertility of male or female rats. Cyclobenzaprine did not demonstrate mutagenic activity in the male mouse at dose levels of up to 20 times the human dose.
</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s18"></a><a name="section-7.6"></a><p></p>
<h2>Pregnancy
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s19"></a><a name="section-7.6.1"></a><p></p>
<p class="First"><span class="Italics">Pregnancy Category B</span></p>
<p>Reproduction studies have been performed in rats, mice and rabbits at doses up to 20 times the human dose, and have revealed no evidence of impaired fertility or harm to the fetus due to cyclobenzaprine HCl. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s20"></a><a name="section-7.7"></a><p></p>
<h2>Nursing Mothers
</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because cyclobenzaprine is closely related to the tricyclic antidepressants, some of which are known to be excreted in human milk, caution should be exercised when cyclobenzaprine HCl is administered to a nursing woman.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s21"></a><a name="section-7.8"></a><p></p>
<h2>Pediatric Use
</h2>
<p class="First">Safety and effectiveness of Fexmid in pediatric patients below 15 years of age have not been established.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s22"></a><a name="section-7.9"></a><p></p>
<h2>Use in the Elderly
</h2>
<p class="First">The plasma concentration of cyclobenzaprine is increased in the elderly (see <span class="Bold"><a href="#s4">CLINICAL PHARMACOLOGY, Pharmacokinetics, </a><a href="#s5">Elderly</a></span>). The elderly may also be more at risk for CNS adverse events such as <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, cardiac events resulting in <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> or other sequelae, drug-drug and drug-disease interactions. For these reasons, in the elderly, Fexmid should be used only if clearly needed. In such patients cyclobenzaprine HCl should be initiated with a 5 mg dose and titrated slowly upward.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s23"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS
</h1>
<p class="First">Incidence of most common adverse reactions in the 2 double-blind<span class="Sup">‡</span>, placebo-controlled 5 mg studies (incidence of &gt; 3% on cyclobenzaprine HCl 5 mg):
</p>
<a name="i63a4300a-a8d1-41fb-85a6-26a5deee9870"></a><table width="100%">
<col align="left" width="12.850%">
<col align="left" width="30.925%">
<col align="left" width="35.050%">
<col align="left" width="21.175%">
<tbody class="Headless">
<tr class="First">
<td align="left" valign="top"></td>
<td align="center" valign="top">Cyclobenzaprine HCl Tablets
</td>
<td align="center" valign="top">Cyclobenzaprine HCl Tablets
</td>
<td align="center" valign="top">Placebo
</td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="center" valign="top">5 mg
</td>
<td align="center" valign="top">10 mg
</td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule" align="left" valign="top"></td>
<td class="Botrule" align="center" valign="top">N=464
</td>
<td class="Botrule" align="center" valign="top">N=249
</td>
<td class="Botrule" align="center" valign="top">N=469
</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span>
</td>
<td align="center" valign="top">29%
</td>
<td align="center" valign="top">38%
</td>
<td align="center" valign="top">10%
</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span>
</td>
<td align="center" valign="top">21%
</td>
<td align="center" valign="top">32%
</td>
<td align="center" valign="top">7%
</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span>
</td>
<td align="center" valign="top">6%
</td>
<td align="center" valign="top">6%
</td>
<td align="center" valign="top">3%
</td>
</tr>
<tr class="Last">
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>
</td>
<td align="center" valign="top">5%
</td>
<td align="center" valign="top">5%
</td>
<td align="center" valign="top">8%
</td>
</tr>
</tbody>
</table>
<p>Adverse reactions which were reported in 1% to 3% of the patients were: <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, acid <span class="product-label-link" type="condition" conceptid="4301596" conceptname="Regurgitation">regurgitation</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, mental acuity decreased, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infection</span>, and <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>.
</p>
<p>The following list of adverse reactions is based on the experience in 473 patients treated with cyclobenzaprine HCl 10 mg in additional controlled clinical studies, 7607 patients in the post-marketing surveillance program, and reports received since the drug was marketed. The overall incidence of adverse reactions among patients in the surveillance program was less than the incidence in the controlled clinical studies.
</p>
<p>The adverse reactions reported most frequently with cyclobenzaprine HCl were <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>. The incidence of these common adverse reactions was lower in the surveillance program than in the controlled clinical studies:
</p>
<a name="i499a0ef7-82e2-493a-8324-4bfc7a9c81b4"></a><table width="100%">
<col align="left" width="15.761%">
<col align="left" width="42.586%">
<col align="left" width="41.653%">
<tbody class="Headless">
<tr class="First">
<td align="left" valign="top"></td>
<td align="center" valign="top"><span class="Bold">Clinical Studies with</span></td>
<td align="center" valign="top"><span class="Bold">Surveillance Program with</span></td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="center" valign="top"><span class="Bold">Cyclobenzaprine HCl Tablets 10 mg</span></td>
<td align="center" valign="top"><span class="Bold">Cyclobenzaprine HCl Tablets 10 mg</span></td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span>
</td>
<td align="center" valign="top">39%
</td>
<td align="center" valign="top">16%
</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span>
</td>
<td align="center" valign="top">27%
</td>
<td align="center" valign="top">7%
</td>
</tr>
<tr class="Last">
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>
</td>
<td align="center" valign="top">11%
</td>
<td align="center" valign="top">3%
</td>
</tr>
</tbody>
</table>
<p>Among the less frequent adverse reactions, there was no appreciable difference in incidence in controlled clinical studies or in the surveillance program. Adverse reactions which were reported in 1% to 3% of the patients were: <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>/<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, unpleasant taste, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>.
</p>
<p>The following adverse reactions have been reported in post-marketing experience or with an incidence of less than 1% of patients in clinical trials with the 10 mg tablet:
</p>
<p><span class="Italics">Body as a Whole:</span> <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span>; <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>.
</p>
<p><span class="Italics">Cardiovascular:</span><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span>; <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>; <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span>; <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>; <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.
</p>
<p><span class="Italics">Digestive:</span> <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>; <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>; <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>; <span class="product-label-link" type="condition" conceptid="4091963" conceptname="Bowel spasm">gastrointestinal pain</span>; <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>; <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>; <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>; <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> of the tongue; abnormal liver function and rare reports of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> and <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span>.
</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>:</span> <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span>; <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>; pruritis; facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>; <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>; <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.
</p>
<p><span class="Italics">Musculoskeletal:</span> Local <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>.
</p>
<p><span class="Italics">Nervous System and Psychiatric:</span> <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>; <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>; <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>; <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>; <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>; <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>; <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">muscle twitching</span>; <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>; <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>; <span class="product-label-link" type="condition" conceptid="40546087" conceptname="Depressed mood">depressed mood</span>; abnormal sensations; <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>; <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>; <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">abnormal thinking</span> and dreaming; <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>; <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span>; <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>; <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>.
</p>
<p><span class="Italics">Skin:</span> <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating</span>.
</p>
<p><span class="Italics">Special Senses:</span> <span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">Ageusia</span>; <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>.
</p>
<p><span class="Italics">Urogenital:</span> <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">Urinary frequency</span> and/or retention.
</p>
<p><span class="Sup">‡</span><span class="Bold Italics">Note: Cyclobenzaprine HCl Tablets 10 mg data are from one clinical trial. Cyclobenzaprine HCl Tablets 5 mg and placebo data are from two studies.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s24"></a><a name="section-8.1"></a><p></p>
<h2>Causal Relationship Unknown
</h2>
<p class="First">Other reactions, reported rarely for cyclobenzaprine HCl under circumstances where a causal relationship could not be established or reported for other tricyclic drugs, are listed to serve as alerting information to physicians:
</p>
<p><span class="Italics">Body as a Whole:</span> <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span>; <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>.
</p>
<p><span class="Italics">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>; <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>; <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>; <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>.
</p>
<p><span class="Italics">Digestive:</span> <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">Paralytic ileus</span>, <span class="product-label-link" type="condition" conceptid="4217621" conceptname="Black hairy tongue">tongue discoloration</span>; <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>; <span class="product-label-link" type="condition" conceptid="4152183" conceptname="Parotid swelling">parotid swelling</span>.
</p>
<p><span class="Italics">Endocrine:</span> <span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">Inappropriate ADH</span> syndrome.
</p>
<p><span class="Italics">Hematic and Lymphatic:</span> <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">Purpura</span>; <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span>; <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>; <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>; <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.
</p>
<p><span class="Italics">Metabolic, Nutritional and Immune:</span> Elevation and lowering of blood sugar levels; <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> or loss.
</p>
<p><span class="Italics">Musculoskeletal:</span> <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span>.
</p>
<p><span class="Italics">Nervous System and Psychiatric:</span> Decreased or <span class="product-label-link" type="condition" conceptid="4237753" conceptname="Increased libido">increased libido</span>; <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">abnormal gait</span>; <span class="product-label-link" type="condition" conceptid="444401" conceptname="Delusions">delusions</span>; <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive behavior</span>; <span class="product-label-link" type="condition" conceptid="432590" conceptname="Delusional disorder">paranoia</span>; <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>; Bell's <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">palsy</span>; alteration in EEG patterns; <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span>.
</p>
<p><span class="Italics">Respiratory:</span> <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span>.
</p>
<p><span class="Italics">Skin:</span> Photosensitization; <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>.
</p>
<p><span class="Italics">Urogenital:</span> Impaired urination; dilatation of urinary tract; <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>; <span class="product-label-link" type="condition" conceptid="4339088" conceptname="Testicular mass">testicular swelling</span>; <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>: <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>; <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">galactorrhea</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="s25"></a><a name="section-9"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span>
</h1>
<p class="First">Pharmacologic similarities among the tricyclic drugs require that certain withdrawal symptoms be considered when Fexmid is administered, even though they have not been reported to occur with this drug. Abrupt cessation of treatment after prolonged administration rarely may produce <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>. These are not indicative of addiction.
</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s26"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE
</h1>
<p class="First">Although rare, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> may occur from overdosage with Fexmid. Multiple drug ingestion (including alcohol) is common in deliberate cyclobenzaprine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. <span class="Bold">As management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> is complex and changing, it is recommended that the physician contact a poison control center for current information on treatment.</span> Signs and symptoms of toxicity may develop rapidly after Fexmid <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>; therefore, hospital monitoring is required as soon as possible. The acute oral LD<span class="Sub">50</span> of cyclobenzaprine HCl is approximately 338 and 425 mg/kg in mice and rats, respectively.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s27"></a><a name="section-10.1"></a><p></p>
<h2>Manifestations
</h2>
<p class="First">The most common effects associated with cyclobenzaprine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> are <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>. Less frequent manifestations include <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span>: <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>. Rare but potentially critical manifestations of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> are <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac dysrhythmias</span>, severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, and <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">neuroleptic malignant syndrome</span>. Changes in the electrocardiogram, particularly in QRS axis or width, are clinically significant indicators of cyclobenzaprine toxicity.
</p>
<p>Other potential effects of overdosage include any of the symptoms listed under <span class="Bold"><a href="#s23">ADVERSE REACTIONS</a>. </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s28"></a><a name="section-10.2"></a><p></p>
<h2>Management
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s29"></a><a name="section-10.2.1"></a><p></p>
<p class="First"><span class="Italics">General</span></p>
<p><span class="Bold">As management of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> is complex and changing, it is recommended that the physician contact a poison control center for current information on treatment.</span></p>
<p>In order to protect against the rare but potentially critical manifestations described above, obtain an ECG and immediately initiate cardiac monitoring. Protect the patient's airway, establish an intravenous line and initiate gastric decontamination. Observation with cardiac monitoring and observation for signs of CNS or <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac dysrhythmias</span> and/or conduction blocks, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> is necessary. If signs of toxicity occur at any time during this period, extended monitoring is required. Monitoring of plasma drug levels should not guide management of the patient. Dialysis is probably of no value because of low plasma concentrations of the drug.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s30"></a><a name="section-10.2.2"></a><p></p>
<p class="First"><span class="Italics">Gastrointestinal Decontamination</span></p>
<p>All patients suspected of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with Fexmid should receive gastrointestinal decontamination. This should include large volume gastric lavage followed by activated charcoal. If consciousness is impaired, the airway should be secured prior to lavage and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> is contraindicated.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s31"></a><a name="section-10.2.3"></a><p></p>
<p class="First"><span class="Italics">Cardiovascular</span></p>
<p>A maximal limb-lead QRS duration of ≥0.10 seconds may be the best indication of the severity of the <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Serum alkalinization, to a pH of 7.45 to 7.55, using intravenous sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> and <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span> (as needed), should be instituted for patients with <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">dysrhythmias</span> and/or QRS widening. A pH &gt; 7.60 or a pCO<span class="Sub">2</span> &lt; 20 mmHg is undesirable. <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Dysrhythmias</span> unresponsive to sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> therapy/<span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span> may respond to lidocaine, bretylium or phenytoin. Type 1A and 1C antiarrhythmics are generally contraindicated (e.g., quinidine, disopyramide, and procainamide).
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s32"></a><a name="section-10.2.4"></a><p></p>
<p class="First"><span class="Italics">CNS</span></p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>, early intubation is advised because of the potential for abrupt deterioration. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> should be controlled with benzodiazepines or, if these are ineffective, other anticonvulsants (e.g. phenobarbital, phenytoin). Physostigmine is not recommended except to treat life-threatening symptoms that have been unresponsive to other therapies, and then only in close consultation with a poison control center.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s33"></a><a name="section-10.3"></a><p></p>
<h2>Psychiatric Follow-Up
</h2>
<p class="First">Since overdosage is often deliberate, patients may attempt <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> by other means during the recovery phase. Psychiatric referral may be appropriate.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s34"></a><a name="section-10.4"></a><p></p>
<h2>Pediatric Management
</h2>
<p class="First">The principles of management of child and adult overdosages are similar. It is strongly recommended that the physician contact the local poison control center for specific pediatric treatment.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s35"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION
</h1>
<p class="First">For most patients, the recommended dose of cyclobenzaprine HCl is 5 mg three times a day. Based on individual patient response, the dose may be increased to either 7.5 mg or 10 mg three times a day. Use of Fexmid for periods longer than two or three weeks is not recommended. (See <span class="Bold"><a href="#s9">INDICATIONS AND USAGE</a></span>.)
</p>
<p>Less frequent dosing should be considered for hepatically impaired or elderly patients (<span class="Bold">see <a href="#s12">PRECAUTIONS, Impaired Hepatic Function,</a></span> and <span class="Bold"><a href="#s22">Use in the Elderly</a></span>).
</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s36"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED
</h1>
<p class="First">Fexmid (cyclobenzaprine hydrochloride tablets USR 7.5 mg) are round, white, film-coated tablets imprinted <span class="Bold">WATSON</span> and <span class="Bold">3330</span> supplied in bottles of 100 (NDC 68453-950-10).
</p>
<p>Dispense in a well-closed container with child-resistant closure.
</p>
<p>Store at 20°-25°C (68°-77°F). [See USP controlled room temperature.]
</p>
<p>Manufactured for:<br>Victory Pharma, Inc.<br>San Diego, CA 92130 USA
</p>
<p>Manufactured by:<br>Watson Laboratories, Inc.<br>Corona, CA 92880 USA
</p>
<p>Issued: October 2007
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PACKAGE LABEL - FEXMID   7.5 MG   TABLETS</h1>
<br><p class="First"><img alt="FEXMID Label Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=615f1e2f-63ec-4e20-bb74-293b5baf1d43&amp;name=FEXMID%207.5%20MG%20LABEL.jpg"></p>
<p><br></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FEXMID 		
					</strong><br><span class="contentTableReg">cyclobenzaprine hydrochloride tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:16590-699(NDC:68453-950)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CYCLOBENZAPRINE HYDROCHLORIDE</strong> (CYCLOBENZAPRINE) </td>
<td class="formItem">CYCLOBENZAPRINE HYDROCHLORIDE</td>
<td class="formItem">7.5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS DIBASIC CALCIUM PHOSPHATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">WATSON;3300</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:16590-699-28</td>
<td class="formItem">28  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:16590-699-60</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:16590-699-90</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA071611</td>
<td class="formItem">11/01/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>STAT Rx USA LLC
							(786036330)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">STAT Rx USA LLC</td>
<td class="formItem"></td>
<td class="formItem">786036330</td>
<td class="formItem">relabel, repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>81cb054f-f32a-40c8-91ed-788fa48aca2c</div>
<div>Set id: 615f1e2f-63ec-4e20-bb74-293b5baf1d43</div>
<div>Version: 1</div>
<div>Effective Time: 20111024</div>
</div>
</div> <div class="DistributorName">STAT Rx USA LLC</div></p>
</body></html>
